EUCTR2007-003228-39-PT进行中（未招募）不适用
A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastatic Hormone-resistant Prostate Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,048
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.Provision of informed consent
- •2.Male, aged 18 years or older
- •3.Histological or cytological confirmation of adenocarcinoma of the prostate
- •4.Documented evidence of bone metastasis on bone scan. Patients must have disease involvement <75% of the spine, pelvis and ribs in the anteroposterior (AP) or posteroanterior (PA) view. Patients with £3 lesions seen on bone scan will require a CT scan, MRI or x-ray to confirm
- •5.Biochemical progression of prostate cancer, documented while the patient is castrate:
- •-Biochemical progression is defined as at least 2 stepwise increases in PSA over a period of =1 month (values do not need to be consecutive but 2 values that have increased since the previous highest value are required) with at least 14 days between each measurement irrespective of assay or laboratory
- •-Historical values may be used
- •-The last PSA must be an increase of =50 % of the first PSA value of the 3 values or an absolute increase of =10 ng/mL over the initial PSA
- •-The final PSA value must be =1.2 ng/mL in patients who have had a radical prostatectomy and = 5ng/mL in all other patients
- •6.Surgically castrated or continuously medically castrated with serum testosterone £2.4 nmol/L (70 ng/dL).
- •7.World Health Organisation (WHO) performance status 0 – 1 (see Appendix E).
- •8.Life expectancy of 3 months or more.
- •For inclusion in the genetic component of the study, patients must fulfil the following criterion:
- •1.Provision of informed consent for genetic research.
- •If a patient declines to participate in the genetic research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study described in this Clinical Study Protocol, so long as they consent to participate.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Radiotherapy to bone lesion or prostatic bed within 4 weeks of starting study treatment
- •2.Prior cytotoxic chemotherapy (such as paclitaxel, docetaxel and mitoxantrone) for the treatment of recurrent prostate cancer (prior estramustine therapy is allowed), as well as other targeted cancer therapies (such as EGF, EGFR, VEGF and VEGFR)
- •3.Systemic radionuclide therapy (ie, strontium chloride Sr89, 186Relabeled HEDP, or 153Sm-EDTMP pentasodium) within 12 weeks of starting study treatment
- •4.Use of potent CYP450 inducers (such as phenytoin, rifampicin, carbamazepine, phenobarbitone, St John’s Wort) within 2 weeks of starting study treatment. Dexamethasone is a known inducer of CYP2D6 and CYP3A4 but is acceptable for this study when used as part of the standard docetaxel regime
- •5.Use of systemic retinoids within 2 weeks of starting study treatment
- •6.Have received investigational drug in another clinical study of anti-cancer therapy, within 4 weeks of starting study treatment
- •7.Prior therapy with endothelin receptor antagonists or family history of hypersensitivity to endothelin antagonists
- •8.Acute or evolving spinal cord compression or neurological symptoms or signs consistent with this. If a patient has neurologic symptoms, an MRI must be performed that demonstrates no impending or actual spinal cord compression. Stable, previously treated patients are allowed
- •9.Symptomatic peripheral neuropathy of CTCAE grade 2 or higher
- •10.Known or suspected central nervous system metastases.
- •11.History of past or current epilepsy, epilepsy syndrome, or other seizure disorder
- •12.Stage II, III or IV cardiac failure (classified according to New York Heart Association (NYHA) classification) or myocardial infarction within 6 months prior to study entry
- •13.QT interval corrected for heart rate eg, by Bazett’s correction >470 msec
- •14.Previous history or presence of another malignancy within the preceding 5 years except treated squamous/basal cell carcinoma of the skin
- •15.In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease, (eg, currently unstable or uncompensated respiratory, cardiac, hepatic or renal disease) or evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study
- •16.Absolute Neutrophil Count (ANC) <1.5 x 109/L (1,500/mm3); haemoglobin (Hb) <9 g/dL; platelet count <100 x 109/L (100,000/mm3). Concomitant use of erythropoietin or blood transfusions is allowed
- •17.Serum bilirubin >1.5 times the upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of haemolysis or hepatic pathology), who will be allowed in consultation with their physician
- •18.Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 times the ULN or 5 times the ULN in the presence of liver metastases
- •19.Creatinine clearance of <50 mL/minute, determined using the Cockcroft-Gault equation or by 24-hour creatinine clearance
- •20.Patients who discontinue after randomisation cannot be re-enrolled. Patients who fail to meet the inclusion/exclusion criteria may be reconsidered once for participation in the study. Patients who are re-enrolled must be re-consented and will be assigned a new enrolment number
- •21.Involvement in the planning and conduct of the study (applies to ICON and AstraZeneca staff or staff a
研究者
相似试验
进行中（未招募）
不适用
A Phase III Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced Non-Small Cell Lung CancerEUCTR2014-000336-42-ESAstraZeneca AB880
进行中（未招募）
1 期
A Phase III Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced Non-Small Cell Lung Cancerocally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III)MedDRA version: 21.1 Level: LLT Classification code 10066490 Term: Progression of non-small cell lung cancer System Organ Class: 100000004864MedDRA version: 21.1 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864EUCTR2014-000336-42-GBAstraZeneca AB1,000
进行中（未招募）
不适用
A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastatic Hormone-resistant Prostate CancerEUCTR2007-003228-39-FIAstraZeneca AB1,044
进行中（未招募）
1 期
A Phase III Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced Non-Small Cell Lung Cancerocally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III)MedDRA version: 20.0Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000336-42-PLAstraZeneca AB713
进行中（未招募）
不适用
A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastatic Hormone-resistant Prostate Cancer - D4320C00033EUCTR2007-003228-39-ITASTRAZENECA1,044